TerminatedPhase 1NCT01341496
Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal
Studying Melanoma of soft tissue
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- David S Schrump, M.D., MD PhD FACPNational Cancer Institute (NCI)
- Intervention
- Epigenetically Modified Autologous Tumor(biological)
- Enrollment
- 41 target
- Eligibility
- 18-99 years · All sexes
- Timeline
- 2011 – 2016
Study locations (1)
- National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01341496 on ClinicalTrials.govOther trials for Melanoma of soft tissue
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06942143An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid TumorsGuangzhou FineImmune Biotechnology Co., LTD.
- RECRUITINGPHASE1NCT06889766NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and SarcomaCentre Hospitalier Universitaire Vaudois
- ACTIVE NOT RECRUITINGNANCT05121545Proton Pencil Beam Scanning GRID for Treatment of Bulky TumorsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- RECRUITINGNCT05231655Ex VIvo DEtermiNed Cancer TherapySheffield Teaching Hospitals NHS Foundation Trust